Navigation Links
AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
Date:2/21/2012

preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the first quarter of 2012 under a grant from the US Army Medical Research and Material Command, or USAMRMC.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... 2014 The global newborn screening market ... technology, product, and geography. The mass spectrometry market ... in the newborn screening market by technology, during ... to various nations opting for expanded newborn screening. ... for expanded newborn screening. Furthermore, various conferences and ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... 11 El Camino Hospital, the hospital of Silicon ... da Vinci® Si HD Surgical Systems. Physicians performed more ... expect the number to increase in 2010 as more ... for more minimally invasive procedures. The new systems feature ...
... BROOMFIELD, Colo., Nov. 11 Accera, Inc., a biotechnology company ... that it will present at Lazard Capital Markets 6th Annual ... in New York. , Steve Orndorff, Ph.D., founder, president ... an update on Axona (TM) on Tuesday, November 17 ...
Cached Medicine Technology:El Camino Hospital Expands Robotic Surgery Program 2El Camino Hospital Expands Robotic Surgery Program 3El Camino Hospital Expands Robotic Surgery Program 4Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference 2
(Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
(Date:10/30/2014)... WA (PRWEB) October 30, 2014 Sound Telecom, ... decision infographic that will assist people any time they wonder, ... discover the right answer by leading them through a series ... resolution to their initial query. , There are many considerations ... not to use an answering service . This decision ...
(Date:10/30/2014)... News) -- Many U.S. colleges have indoor tanning ... increases the risk for skin cancer, researchers report. ... white women, so colleges should adopt tanning-free policies, ... "Public health efforts are needed to raise ... harms that indoor tanning poses to young adults ...
(Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:New insights into the development of ciliopathies 2
... the seventh leading cause of cancer death worldwide, the ... group and gender. Esophageal cancer is thought to be ... with the host genome. Researchers have long been seeking ... conducted on gene-environment interaction and gene polymorphisms for esophageal ...
... intellectual property laws devalue the "repurposing" of existing ... life-saving treatments, a Portland researcher contends. , S. ... behavioral neuroscience in the Oregon Health & Science ... Affairs Medical Center, writes in a letter appearing ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... severe Alzheimer,s disease for the quarter ended June ... royalty payments compared to,the same quarter last year, ...
... Oct. 31 MAP,Pharmaceuticals, Inc. (Nasdaq: ... the initiation of a Phase 2a clinical ... asthma and chronic obstructive,pulmonary disease (COPD). ... and a long-acting,beta2-agonist delivered to the respiratory ...
... and Offshore Healthcare Expertise and ... Service Delivery Capabilities EL SEGUNDO, Calif. ... CSC ) and,First Consulting Group, Inc. (Nasdaq: FCGI ) today ... through which CSC will acquire,First Consulting Group (FCG) in an all-cash ...
... EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Rodman and Renshaw 9th Annual Healthcare Conference in ... 3:20 pm (Local Time), WHERE: New York ...
Cached Medicine News:Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Old drugs need 'repurposing' for new uses, physician says 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:CSC Agrees to Acquire First Consulting Group 2Health News:CSC Agrees to Acquire First Consulting Group 3Health News:CSC Agrees to Acquire First Consulting Group 4Health News:CSC Agrees to Acquire First Consulting Group 5Health News:BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: